Market Overview

Benzinga's Top Initiations

Related ARWR
Arrowhead Files For Regulatory Permission To Begin Phase 1 Trial Of RNAi Therapeutic ARC-AAT
Arrowhead Offers Data on ARC-520, ARC-AAT at AASLD The Liver Meeting
Related FMI
Foundation Medicine Signs Data Partnership With Cota, Inc
Foundation Medicine And WuXi PharmaTech Announce Strategic Collaboration To Offer Best-in-Class Comprehensive Genomic Profiling in China

Analysts at Piper Jaffray initiated coverage on shares of Arrowhead Research (NASDAQ: ARWR) with an “overweight” rating. The target price for Arrowhead Research is set to $12. Arrowhead Research's shares closed at $7.87 on Friday.

Analysts at Goldman Sachs initiated coverage on shares of Foundation Medicine (NASDAQ: FMI) with a “neutral” rating. The target price for Foundation Medicine is set to $33. Foundation Medicine's stock closed at $33.99 on Friday.

JP Morgan initiated coverage on shares of Premier (NASDAQ: PINC) with an “overweight” rating. The target price for Premier is set to $36. Premier's shares closed at $31.66 on Friday.

Morgan Stanley initiated coverage on shares of Ophthotech (NASDAQ: OPHT) with an “overweight” rating. The target price for Ophthotech is set to $56. Ophthotech's shares closed at $29.25 on Friday.

Latest Ratings for ARWR

DateFirmActionFromTo
Oct 2014RBC CapitalDowngradesOutperformSector Perform
Oct 2014Deutsche BankMaintainsBuy
Mar 2014Deutsche BankInitiates Coverage onBuy

View More Analyst Ratings for ARWR
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Related Articles (ARWR + FMI)

Around the Web, We're Loving...

Get Benzinga's Newsletters